Paper Details

  1. Home
  2. Paper Details

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.

Author: BengtssonN-O, BerghJ, FoukakisT, GnantM, GreilR, HellströmM, JohanssonH, LoiblS, MalmströmP, MatikasA, MoebusV, StegerG G, UntchM

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adjuvant chemotherapy (ACT) can improve outcomes for breast cancer patients. This study evaluated the efficacy of tailored dosing of ACT in a clinical trial.
Paper Details　
Original Abstract of the Article :
Adjuvant chemotherapy (ACT) for breast cancer improves relapse-free survival (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could partly be explained by the significant interpatient variability in pharmacokinetics which cannot be captured by dosing according to body surf...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mdy475

データ提供：米国国立医学図書館（NLM）

Tailoring Adjuvant Chemotherapy for Breast Cancer: The PANTHER Study

This research delves into the area of [oncology] and focuses on the optimization of adjuvant chemotherapy for breast cancer. The authors present further results from the prospective PANTHER study, investigating the concept of dose tailoring based on hematologic toxicities. The study uses [prospective clinical trial data] to explore how adjusting chemotherapy doses based on individual patient responses can improve outcomes. They particularly investigated the efficacy of dose tailoring in obese patients.

Personalized Chemotherapy: A Camel's Perspective

Imagine a vast desert landscape where each sand dune is unique, shaped by the winds and forces of nature. This research is similar, emphasizing the individuality of each patient and the need for personalized treatment approaches. The study demonstrates that dose tailoring can improve the effectiveness of chemotherapy while minimizing side effects, creating a more tailored treatment experience for each individual.

Optimizing Breast Cancer Treatment: A Camel's Perspective

As a camel who has navigated the harsh realities of the desert, I understand the importance of finding ways to adapt and thrive. This research provides valuable insights into how we can adapt chemotherapy regimens to optimize outcomes for breast cancer patients. By tailoring treatment based on individual responses, we can minimize toxicity while maximizing efficacy, leading to a more positive and successful treatment experience.

Dr.Camel's Conclusion

This study underscores the importance of individualized treatment approaches in oncology. The PANTHER study demonstrates that dose tailoring can be an effective strategy for improving both efficacy and safety of adjuvant chemotherapy for breast cancer. This research reinforces the need for personalized medicine and tailored treatment plans, as each patient's journey is unique.

Date :
  1. Date Completed 2020-03-04
  2. Date Revised 2020-03-27
Further Info :

Pubmed ID

30357310

DOI: Digital Object Identifier

10.1093/annonc/mdy475

Related Literature

Article Analysis
・Side Effects of epirubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.